Amarin's Vascepa Momentum Builds Ahead Of Next Week's FDA AdComm

Sales of the triglyceride-lowering medicine soared to $112.4m in the third quarter even before a label expansion that depends on the outcome of a vital US FDA advisory committee meeting on 14 November.